Heparan sulfate-dependent enhancement of henipavirus infection

mBio

Volumn 6, Issue 2, 2015, Pages

  Mathieu, Cyrille ^a,b,c   Dhondt, Kévin P ^a,b,c   Châlons, Marie ^a,b,c   Mély, Stéphane ^d   Raoul, Hervé ^d   Negre, Didier ^a,b,c   Cosset, François Loïc ^a,b,c   Gerlier, Denis ^a,b,c   Vivès, Romain R ^e,f,g   Horvat, Branka ^a,b,c  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE LYON   (France)

^d INSERM   (France)

^e UNIV GRENOBLE ALPES   (France)

^f INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^g CEA GRENOBLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; EPHRIN B3; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HENDRA VIRUS; HENDRA VIRUS INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NIPAH VIRUS; NIPAH VIRUS INFECTION; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; SYRIAN HAMSTER; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; ANIMAL; CELL CULTURE; HAMSTER; HENIPAVIRUS INFECTION; LEUKOCYTE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SURFACE PLASMON RESONANCE; SURVIVAL ANALYSIS; VIROLOGY;

ANIMALIA; CRICETINAE; HENDRA VIRUS; HENIPAVIRUS; MAMMALIA; NIPAH VIRUS;

ANIMALS; CELLS, CULTURED; CRICETINAE; HENDRA VIRUS; HENIPAVIRUS INFECTIONS; HEPARITIN SULFATE; HUMANS; LEUKOCYTES; NIPAH VIRUS; SURFACE PLASMON RESONANCE; SURVIVAL ANALYSIS; VIRUS ATTACHMENT;

EID: 84929501222     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02427-14     Document Type: Article

References (52)

1. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, Westbury H, Hiley L, Selvey L, Rodwell B, Ketterer P. 1995. A morbillivirus that caused fatal disease in horses and humans. Science 268:94-97. http://dx.doi.org/10.1126/science.7701348.
2. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh W, Goldsmith CS, Gubler DJ, Roehrig JT, Eaton B, Gould AR, Olson J, Field H, Daniels P, Ling AE, Peters CJ, Anderson LJ, Mahy BW. 2000. Nipah virus: a recently emergent deadly paramyxovirus. Science 288:1432-1435. http://dx.doi.org/10.1126/science.288.5470.1432.
3. Marsh GA, Wang LF. 2012. Hendra and Nipah viruses: why are they so deadly? Curr Opin Virol 2:242-247. http://dx.doi.org/10.1016/j.coviro.2012.03.006.
4. Lam SK. 2003. Nipah virus—a potential agent of bioterrorism? Antiviral Res 57:113-119. http://dx.doi.org/10.1016/S0166-3542(02)00204-8.
5. Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, Bishop KA, Choudhry V, Dimitrov DS, Wang L-F, Eaton BT, Broder CC. 2005. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acd SciUSA102:10652-10657. http://dx.doi.org/10.1073/pnas.0504887102.
6. Negrete OA, Levroney EL, Aguilar HC, Bertolotti-Ciarlet A, Nazarian R, Tajyar S, Lee B. 2005. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436:401-405. http://dx.doi.org/10.1038/nature03838.
7. Negrete OA, Wolf MC, Aguilar HC, Enterlein S, Wang W, Mühlberger E, Su SV, Bertolotti-Ciarlet A, Flick R, Lee B. 2006. Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog 2:e7. http://dx.doi.org/10.1371/journal.ppat.0020007.
8. Mathieu C, Pohl C, Szecsi J, Trajkovic-Bodennec S, Devergnas S, Raoul H, Cosset FL, Gerlier D, Wild TF, Horvat B. 2011. Nipah virus uses leukocytes for efficient dissemination within a host. J Virol 85:7863-7871. http://dx.doi.org/10.1128/JVI.00549-11.
9. Bobardt MD, Saphire AC, Hung H-C, Yu X, Van der Schueren B, Zhang Z, David G, Gallay PA. 2003. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18:27-39. http://dx.doi.org/10.1016/S1074-7613(02)00504-6.
10. Piñon JD, Klasse PJ, Jassal SR, Welson S, Weber J, Brighty DW, Sattentau QJ. 2003. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 77:9922-9930. http://dx.doi.org/10.1128/JVI.77.18.9922-9930.2003.
11. Vivès RR, Lortat-Jacob H, Fender P. 2006. Heparan sulphate proteoglycans and viral vectors: ally or foe? Curr Gene Ther 6:35-44. http://dx.doi.org/10.2174/156652306775515565.
12. Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777. http://dx.doi.org/10.1146/annurev.biochem.68.1.729.
13. Bourin MC, Lindahl U. 1993. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 289:313-330.
14. Lever R, Page CP. 2002. Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140-148. http://dx.doi.org/10.1038/nrd724.
15. Rostand KS, Esko JD. 1997. Microbial adherence to and invasion through proteoglycans. Infect Immun 65:1-8.
16. Spillmann D. 2001. Heparan sulfate: anchor for viral intruders? Biochimie 83:811-817. http://dx.doi.org/10.1016/S0300-9084(01)01290-1.
17. Holen HL, Zernichow L, Fjelland KE, Evenroed IM, Prydz K, Tveit H, Aasheim H-C. 2011. Ephrin-B3 binds to a sulfated cell-surface receptor. Biochem J 433:215-223. http://dx.doi.org/10.1042/BJ20100865.
18. Lam LH, Silbert JE, Rosenberg RD. 1976. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69:570-577. http://dx.doi.org/10.1016/0006-291X(76)90558-1.
19. Kusche M, Bäckström G, Riesenfeld J, Petitou M, Choay J, Lindahl U. 1988. Biosynthesis of heparin. O-sulfation of the antithrombin-binding region. J Biol Chem 263:15474-15484.
20. Wong KT, Grosjean I, Brisson C, Blanquier B, Fevre-Montange M, Bernard A, Loth P, Georges-Courbot M-C, Chevallier M, Akaoka H, Marianneau P, Lam SK, Wild TF, Deubel V. 2003. A golden hamster model for human acute Nipah virus infection. Am J Pathol 163: 2127-2137. http://dx.doi.org/10.1016/S0002-9440(10)63569-9.
21. Stachowiak B, Weingartl HM. 2012. Nipah virus infects specific subsets of porcine peripheral blood mononuclear cells. PLoS One 7:e30855. http://dx.doi.org/10.1371/journal.pone.0030855.
22. Akiyama H, Miller C, Patel HV, Hatch SC, Archer J, Ramirez NG, Gummuluru S. 2014. Virus particle release from glycosphingolipidenriched microdomains is essential for dendritic cell-mediated capture and transfer of HIV-1 and henipavirus. J Virol 88:8813-8825. http://dx.doi.org/10.1128/JVI.00992-14.
23. Mondor I, Ugolini S, Sattentau QJ. 1998. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 72:3623-3634.
24. Vivès RR, Imberty A, Sattentau QJ, Lortat-Jacob H. 2005. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 280:21353-21357. http://dx.doi.org/10.1074/jbc.M500911200.
25. Chung CS, Hsiao JC, Chang YS, Chang W. 1998. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 72: 1577-1585.
26. Terao-Muto Y, Yoneda M, Seki T, Watanabe A, Tsukiyama-Kohara K, Fujita K, Kai C. 2008. Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines. Antiviral Res 80: 370-376. http://dx.doi.org/10.1016/j.antiviral.2008.08.006.
27. Feldman SA, Audet S, Beeler JA. 2000. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 74:6442-6447. http://dx.doi.org/10.1128/JVI.74.14.6442-6447.2000.
28. Chang A, Masante C, Buchholz UJ, Dutch RE. 2012. Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol 86: 3230-3243. http://dx.doi.org/10.1128/JVI.06706-11.
29. Fujita K, Miura R, Yoneda M, Shimizu F, Sato H, Muto Y, Endo Y, Tsukiyama-Kohara K, Kai C. 2007. Host range and receptor utilization of canine distemper virus analyzed by recombinant viruses: involvement of heparin-like molecule in CDV infection. Virology 359:324-335. http://dx.doi.org/10.1016/j.virol.2006.09.018.
30. Karger A, Schmidt U, Buchholz UJ. 2001. Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J Gen Virol 82:631-640.
31. Guibinga GH, Miyanohara A, Esko JD, Friedmann T. 2002. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 5:538-546. http://dx.doi.org/10.1006/mthe.2002.0578.
32. Richards KF, Bienkowska-Haba M, Dasgupta J, Chen XS, Sapp M. 2013. Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol 87: 11426-11437. http://dx.doi.org/10.1128/JVI.01721-13.
33. Zhu Z, Gershon MD, Ambron R, Gabel C, Gershon AA. 1995. Infection of cells by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin. Proc Natl Acad Sci U S A 92:3546-3550. http://dx.doi.org/10.1073/pnas.92.8.3546.
34. Ranjbaran H, Wang Y, Manes TD, Yakimov AO, Akhtar S, Kluger MS, Pober JS, Tellides G. 2006. Heparin displaces interferon-gammainducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation 114:1293-1300. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.631457.
35. Mathieu C, Guillaume V, Sabine A, Ong KC, Wong KT, Legras-Lachuer C, Horvat B. 2012. Lethal Nipah virus infection induces rapid overexpression of CXCL 10. PLoS One 7:e32157. http://dx.doi.org/10.1371/journal.pone.0032157.
36. Floris S, van den Born J, van der Pol SM, Dijkstra CD, De Vries HE. 2003. Heparan sulfate proteoglycans modulate monocyte migration across cerebral endothelium. J Neuropathol Exp Neurol 62:780-790.
37. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. 1998. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 101:877-889. http://dx.doi.org/10.1172/JCI1509.
38. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Piqué JM, Panés J. 2000. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 47:88-96. http://dx.doi.org/10.1136/gut.47.1.88.
39. Skinner MP, Lucas CM, Burns GF, Chesterman CN, Berndt MC. 1991. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem 266:5371-5374.
40. Urbinati C, Chiodelli P, Rusnati M. 2008. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 13:2758-2785. http://dx.doi.org/10.3390/molecules13112758.
41. Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, Trono D, Van der Schueren B, David G, Gallay PA. 2004. Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol 78:6567-6584. http://dx.doi.org/10.1128/JVI.78.12.6567-6584.2004.
42. Lee E, Pavy M, Young N, Freeman C, Lobigs M. 2006. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res 69:31-38. http://dx.doi.org/10.1016/j.antiviral.2005.08.006.
43. Cagno V, Donalisio M, Civra A, Volante M, Veccelli E, Oreste P, Rusnati M, Lembo D. 2014. Highly sulfated k5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures. Antimicrob Agents Chemother 58:4782-4794. http://dx.doi.org/10.1128/AAC.02594-14.
44. Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U. 2012. A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis 205:1654-1664. http://dx.doi.org/10.1093/infdis/jis273.
45. Yoneda M, Guillaume V, Ikeda F, Sakuma Y, Sato H, Wild TF, Kai C. 2006. Establishment of a Nipah virus rescue system. Proc Natl Acad Sci U S A 103:16508-16513. http://dx.doi.org/10.1073/pnas.0606972103.
46. Guillaume V, Wong KT, Looi RY, Georges-Courbot M-C, Barrot L, Buckland R, Wild TF, Horvat B. 2009. Acute Hendra virus infection: analysis of the pathogenesis and passive antibody protection in the hamster model. Virology 387:459-465. http://dx.doi.org/10.1016/j.virol.2009.03.001.
47. Guillaume V, Lefeuvre A, Faure C, Marianneau P, Buckland R, Lam SK, Wild TF, Deubel V. 2004. Specific detection of Nipah virus using realtime RT-PCR (TaqMan). J Virol Methods 120:229-237. http://dx.doi.org/10.1016/j.jviromet.2004.05.018.
48. Horvat B, Rivailler P, Varior-Krishnan G, Cardoso A, Gerlier D, Rabourdin-Combe C. 1996. Transgenic mice expressing human measles virus (MV) receptor CD46 provide cells exhibiting different permissivities to MV infections. J Virol 70:6673-6681.
49. Vivès RR, Sadir R, Imberty A, Rencurosi A, Lortat-Jacob H. 2002. A kinetics and modeling study of RANTES(9-68) binding to heparin reveals a mechanism of cooperative oligomerization. Biochemistry 41: 14779-14789. http://dx.doi.org/10.1021/bi026459i.
50. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45. http://dx.doi.org/10.1093/nar/29.9.e45.
51. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611-622. http://dx.doi.org/10.1373/clinchem.2008.112797.
52. Ono K, Ishihara M, Ishikawa K, Ozeki Y, Deguchi H, Sato M, Hashimoto H, Saito Y, Yura H, Kurita A, Maehara T. 2002. Periodatetreated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br J Cancer 86:1803-1812. http://dx.doi.org/10.1038/sj.bjc.6600307.